ARTICLE | Clinical News
Kyprolis carfilzomib regulatory update
September 21, 2015 7:00 AM UTC
Ono submitted a regulatory application in Japan for Kyprolis carfilzomib to treat relapsed or refractory multiple myeloma (MM). The selective proteasome inhibitor is approved in the U.S. and is under ...